Pyridine Carboxamides: Potent Palm Site Inhibitors of HCV NS5B Polymerase
摘要:
Pyridine carboxamide-based inhibitors of the hepatitis C virus (HCV) NS5B polymerase were diversified and optimized to a variety of topologically related scaffolds. In particular, the 2-methyl nicotinic acid scaffold was developed into inhibitors with improved biochemical (IC50-GT1b = 0.014 mu M) and cell-based HCV replicon potency (EC50-GT1b = 0.7 mu M). Biophysical and biochemical characterization identified this novel series of compounds as palm site binders to HCV polymerase.
1,4-SUBSTITUTED PIPERAZINE DERIVATIVES AND METHODS OF USE THEREOF
申请人:Cheng Cliff C.
公开号:US20130164259A1
公开(公告)日:2013-06-27
The present invention relates to 1,4-Substituted Piperazine Derivatives, compositions comprising one or more 1,4-Substituted Piperazine Derivatives, and methods of using the 1,4-Substituted Piperazine Derivatives for treating or preventing a viral infection or a virus-related disorder in a patient.
[EN] 1,4-SUBSTITUTED PIPERAZINE DERIVATIVES AND METHODS OF USE THEREOF<br/>[FR] DÉRIVÉS DE PIPÉRAZINE 1,4-SUBSTITUÉS ET PROCÉDÉS D'UTILISATION DE CEUX-CI
申请人:SCHERING CORP
公开号:WO2011087738A2
公开(公告)日:2011-07-21
The present invention relates to 1,4-Substituted Piperazine Derivatives, compositions comprising one or more 1,4-Substituted Piperazine Derivatives, and methods of using the 1,4-Substituted Piperazine Derivatives for treating or preventing a viral infection or a virus-related disorder in a patient.
Pyridine Carboxamides: Potent Palm Site Inhibitors of HCV NS5B Polymerase
作者:Cliff C. Cheng、Xiaohua Huang、Gerald W. Shipps、Yu-Sen Wang、Daniel F. Wyss、Kyle A. Soucy、Chuan-kui Jiang、Sony Agrawal、Eric Ferrari、Zhiqing He、H.-C. Huang
DOI:10.1021/ml100128h
日期:2010.12.9
Pyridine carboxamide-based inhibitors of the hepatitis C virus (HCV) NS5B polymerase were diversified and optimized to a variety of topologically related scaffolds. In particular, the 2-methyl nicotinic acid scaffold was developed into inhibitors with improved biochemical (IC50-GT1b = 0.014 mu M) and cell-based HCV replicon potency (EC50-GT1b = 0.7 mu M). Biophysical and biochemical characterization identified this novel series of compounds as palm site binders to HCV polymerase.